Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Very interesting and enlightening article indeed. But I differ from authors at one place where they say -
"......has led to two major developments in cervical cancer control: immunisation as a means of primary prevention and HPV testing in cervical screening, which is poised to replace cytology as the primary screening modality."
Not all cervical cancers are HPV 16 and 18 and 30% are caused by other types, for which HPV quadrivalent vaccine is uneffective. As currently no antiviral agent for cure of HPV is existent, we need to do screening for identification of HPV as said by authors.
However, we need to do cytology for detecting cervical intraepithelial neoplasia (CIN) in order to exise the affected tissue (cone biopsy) as this is the only cure as there is no antiviral agent. More so, for the non 16 and 18 types of HPV for which there is no prevention and cone biopsy is the only cure.